{"url_path":"/sec/zsqr/8-k/2026-06-01/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1759186/0001683168-26-004425-index.html","accession_number":"0001683168-26-004425","cik":"0001759186","ticker":"ZSQR","issuer_name":"Z Squared Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1759186/0001683168-26-004425-index.html","primary_entity_key":"0001759186","primary_entity_name":"Z Squared Inc."},"word_count":696,"has_tables":true,"body_markdown":"COEPTIS THERAPEUTICS HOLDINGS, INC. 8-K\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE\nCOMMISSION**\n\n**Washington, D.C. 20549**\n\n**_____________________**\n\n**FORM 8-K/A**\n\n**(Amendment No. 1)**\n\n**_____________________**\n\n \n\n**CURRENT REPORT**\n\n**PURSUANT TO SECTION 13 OR 15(d)**\n\n**OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nDate of Report (Date of Earliest Event Reported):\n**April 24, 2026**\n\n**_____________________**\n\n \n\n**Z\nSquared Inc.**\n\n(Exact name of registrant as specified in its\ncharter) ****\n\n \n\n**Delaware**\n**001-39669**\n**98-1465952**\n\n(State or other jurisdiction\n\nof incorporation)\n\n(Commission\n\nFile Number)\n\n(I.R.S. Employer\n\nIdentification No.)\n\n \n \n \n\n**550\nSouth Andrews Ave., Suite\n#700**\n\n**Fort\nLauderdale, Florida**\n\n \n**33301**\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n \n\n**954-400-9994**\n\n(Registrant’s telephone number,\nincluding area code)\n\n \n\n**Coeptis Therapeutics Holdings, Inc.**\n\n(Former name or former address, if changed since\nlast report)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n \n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n \n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n \n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n \n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\n**Securities registered\npursuant to Section 12(b) of the Act:**\n\n \n\nTitle of\neach class\n \n\nTrading Symbol(s)\n\n \n\nName\nof each exchange on which registered\n\n**Common Stock, par value $0.0001 per share**\n\n \n\n**ZSQR**\n\n \n\n**The Nasdaq\nStock Market LLC**\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange\nAct of 1934 (§240.12b-2 of this chapter). \n\nEmerging growth company     ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act.      ☐\n\n \n\n \n\n \n\n \n\n   \n\n \n\n \n\n**EXPLANATORY NOTE**\n\n \n\nThis Amendment No. 1 on Form 8-K/A (this “Amendment”)\nis being filed by Z Squared Inc. (formerly known as Coeptis Therapeutics Holdings, Inc.), a Delaware corporation (the “Company”),\nto amend the Current Report on Form 8-K originally filed by the Company with the Securities and Exchange Commission on April 30, 2026\n(the “Original Report”), which reported, among other things, the completion on April 24, 2026 (the “Closing Date”)\nof the merger of CP Merger Sub, Inc., a Wyoming corporation and wholly owned direct subsidiary of the Company, with and into Z Squared\nInc., a Wyoming corporation (“Z Squared Wyoming”), with Z Squared Wyoming surviving the merger as a wholly owned subsidiary\nof the Company and changing its name to Z Squared OpCo Inc. (“OpCo”) (the “Merger”). The Merger is being accounted\nfor as a reverse acquisition under ASC 805-40, with OpCo treated as the accounting acquirer for financial reporting purposes.\n\n \n\nThis Amendment is being filed for the purpose\nof (i) providing the financial statements of the business acquired required by Item 9.01(a) of Form 8-K that were not included in the\nOriginal Report in reliance on the provisions of Item 9.01(a)(4) of Form 8-K, which permitted such financial statements to be filed by\namendment to the Original Report not later than 71 calendar days after the date that the Original Report was required to be filed, and\n(ii) supplementing and updating the unaudited pro forma condensed combined financial information previously filed as Exhibit 99.1 to the\nOriginal Report to include unaudited pro forma condensed combined financial information as of and for the three months ended March 31,\n2026, which reflects the historical financial information of the legal acquirer for the most recent interim period and which was not available\nat the time the Original Report was filed.\n\n \n\nExcept as set forth herein, no other modifications\nare being made to the Original Report. This Amendment does not amend, modify or update any other disclosures contained in the Original\nReport, and the information contained in the Original Report has not been otherwise updated to reflect events occurring after the date\nof the Original Report. Accordingly, this Amendment should be read in conjunction with the Original Report and the Company’s other\nfilings with the Securities and Exchange Commission.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 2"}